PATENT CLAIM ANALYSIS

Application Number: 15897947
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-06
Patent Classification: ["514", "275000"]

Abstract:
Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid form or a salt form, such as a disodium salt form, can be used to treat or alleviate pain or related conditions, such as low back pain.

Claim (Index 16):
The method of  claim 13 , wherein a weekly dose of about 50 mg to about 100 mg of the zoledronic acid in the disodium salt form is orally administered to the human being.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 88.0
- Lexical Diversity: 1.53333
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15403073', '15697267', '15416995', '15439774', '15587108']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8632430115279986
- 35 USC 102 Novelty (BERT): 0.6326502784415428
- Combined Prediction Score: 0.8401837382193531
- Mean Citation Score: 648.307588
- Max Citation Score: 676.0469
- Similarity Product: 538.3471430893541

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test